Dostinex Related Published Studies
Well-designed clinical trials related to Dostinex (Cabergoline)
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. [2007.08]
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.04.15]
Cabergoline compared to levodopa in the treatment of patients with severe restless legs syndrome: Results from a multi-center, randomized, active controlled trial. [2007.02.01]
Salvage of sildenafil failures with cabergoline: a randomized, double-blind, placebo-controlled study. [2006.11]
Efficacy of cabergoline in restless legs syndrome: a placebo-controlled study with polysomnography (CATOR). [2006.09.26]
Randomized controlled pilot trial of cabergoline, hydergine and levodopa/carbidopa: Los Angeles Cocaine Rapid Efficacy Screening Trial (CREST). [2005.03]
Effective cabergoline treatment in idiopathic restless legs syndrome. [2004.12.28]
Enhancement of the efficacy of weekly low-dose taxotere by the long acting anti-prolactinemic drug cabergoline in pretreated metastatic breast cancer. [2004.11]
Biological response modifiers of cancer-related neuroendocrine disorders: efficacy of the long-term dopaminergic agonist cabergoline in the treatment of breast cancer-induced hyperprolactinemia. [2004.07]
[Cabergoline for inhibition of lactation] [2004.01]
The long-acting dopamine receptor agonist cabergoline in early Parkinson's disease: final results of a 5-year, double-blind, levodopa-controlled study. [2004]
Evaluation of cabergoline and buserelin efficacy for oestrous induction in the bitch. [2003.12]
Cabergoline, pramipexole and ropinirole used as monotherapy in early Parkinson's disease: an evidence-based comparison. [2003]
Control of fertility in the red fox (Vulpes vulpes): effect of a single oral dose of cabergoline in early pregnancy. [2002]
Effectiveness of cabergoline for termination of pregnancy in silver fox (Vulpes vulpes fulva). [2001.10]
Comparison of the effects of cabergoline and bromocriptine on prolactin levels in hyperprolactinemic patients. [2001.09]
Control of red fox (Vulpes vulpes) fertility with cabergoline: dose response and timing of intervention. [2001.07]
Clinical data on restless legs syndrome: a dose-finding study with cabergoline. [2001]
A randomized cross-over study comparing cabergoline and quinagolide in the treatment of hyperprolactinemic patients. [2000.07]
Hormone levels and tumour size response to quinagolide and cabergoline in patients with prolactin-secreting and clinically non-functioning pituitary adenomas: predictive value of pituitary scintigraphy with 123I-methoxybenzamide. [2000.04]
Effect of chronic administration of cabergoline on uterine perfusion in women with polycystic ovary syndrome. [1999.02]
Cabergoline treatment rapidly improves gonadal function in hyperprolactinemic males: a comparison with bromocriptine. [1998.03]
Early treatment of Parkinson's disease with cabergoline delays the onset of motor complications. Results of a double-blind levodopa controlled trial. The PKDS009 Study Group. [1998]
Cabergoline in the treatment of early Parkinson's disease: results of the first year of treatment in a double-blind comparison of cabergoline and levodopa. The PKDS009 Collaborative Study Group. [1997.02]
[Treatment of hyperprolactinemic amenorrhea with cabergoline] [1997]
The chronic administration of cabergoline normalizes androgen secretion and improves menstrual cyclicity in women with polycystic ovary syndrome. [1996.10]
Double-blind comparison of cabergoline and bromocriptine in Parkinson's disease patients with motor fluctuations. [1996.09]
The effect of food on cabergoline pharmacokinetics and tolerability in healthy volunteers. [1996.07]
Multicenter, placebo-controlled trial of cabergoline taken once daily in the treatment of Parkinson's disease. [1996.04]
Double-blind study of the activity and tolerability of cabergoline versus placebo in parkinsonians with motor fluctuations. [1996.01]
[Hyperprolactinemic amenorrhea:treatment with cabergoline versus bromocriptine. Results of a national multicenter randomized double-blind study] [1995.04.29]
Fluctuating Parkinson's disease. Treatment with the long-acting dopamine agonist cabergoline. [1994.12]
A comparison of cabergoline and bromocriptine in the treatment of hyperprolactinemic amenorrhea. Cabergoline Comparative Study Group. [1994.10.06]
Pharmacodynamics and relative bioavailability of cabergoline tablets vs solution in healthy volunteers. [1994.10]
A cross-over study with the two novel dopaminergic drugs cabergoline and quinagolide in hyperprolactinemic patients. [1994.01]
Multicenter study of cabergoline, a long-acting dopamine receptor agonist, in Parkinson's disease patients with fluctuating responses to levodopa/carbidopa. [1993.10]
Controlled study of the antiparkinsonian activity and tolerability of cabergoline. [1993.03]
Dose-dependent suppression of serum prolactin by cabergoline in hyperprolactinaemia: a placebo controlled, double blind, multicentre study. European Multicentre Cabergoline Dose-finding Study Group. [1992.12]
Oral cabergoline. Single-dose inhibition of puerperal lactation. [1991.10]
Cabergoline versus bromocriptine in suppression of lactation after cesarean delivery. [1991]
Long-lasting lowering of serum growth hormone and prolactin levels by single and repetitive cabergoline administration in dopamine-responsive acromegalic patients. [1988.11]
Prevention of puerperal lactation by a single oral administration of the new prolactin-inhibiting drug, cabergoline. [1988.03]
Prolactin-lowering effect of acute and once weekly repetitive oral administration of cabergoline at two dose levels in hyperprolactinemic patients. [1988.01]
Well-designed clinical trials possibly related to Dostinex (Cabergoline)
Repeated induction of abortion in bitches and the effect on plasma concentrations of relaxin, progesterone and estradiol-17beta. [2007.10.01]
Modification of practice-dependent plasticity in human motor cortex by neuromodulators. [2006.08]
Clinical inquiries. What is the recommended evaluation and treatment for elevated serum prolactin? [2005.10]
Cocaine Rapid Efficacy Screening Trial (CREST): a paradigm for the controlled evaluation of candidate medications for cocaine dependence. [2005.03]
Study of the change of prolactin and progesterone during dopaminergic agonist treatments in pseudopregnant bitches. [2001.05.31]
Other research related to Dostinex (Cabergoline)
Cabergoline and cardiac valve disease in prolactinoma patients: additional studies during long-term treatment are required. [2008.10]
Low dose cabergoline for hyperprolactinaemia is not associated with clinically significant valvular heart disease. [2008.10]
Cushing's disease in dogs: cabergoline treatment. [2008.08]
Cabergoline and the risk of valvular lesions in endocrine disease. [2008.07]
[Two cases of patients with Parkinson's disease developing valvular heart disease while taking cabergoline] [2008.07]
Cabergoline-induced psychotic exacerbation in schizophrenic patients. [2008.07]
Case study of a 15-year-old boy with McCune-Albright syndrome combined with pituitary gigantism: effect of octreotide-long acting release (LAR) and cabergoline therapy. [2008.07]
TSH-secreting adenoma improved with cabergoline. [2008.06]
A case of constrictive pericarditis during cabergoline treatment for hyperprolactinaemia. [2008.04]
Cabergoline-associated erythema nodosum. [2008.02]
Conversion from dopamine agonists to cabergoline: an open-label trial in 128 patients with advanced Parkinson disease. [2008.01]
Remarkable effects of cabergoline in a patient with huge prolactinoma resistant to high-dose bromocriptine: case report. [2008.01]
Cabergoline for suppression of puerperal lactation in a prevention of mother-to-child HIV-transmission programme in rural Malawi. [2008.01]
Influence of cabergoline on motor excitability in patients with restless legs syndrome. [2007.12]
Implantation is apparently unaffected by the dopamine agonist Cabergoline when administered to prevent ovarian hyperstimulation syndrome in women undergoing assisted reproduction treatment: a pilot study. [2007.12]
[Aortic insufficiency under weak doses of cabergoline for non-tumoral hyperprolactinemia] [2007.12]
Follicular development and plasma concentrations of LH and prolactin in anestrous female dogs treated with the dopamine agonist cabergoline. [2007.10.01]
[Mitral valve replacement for cabergoline-related severe mitral regurgitation] [2007.10]
The effects of a low dose of cabergoline on induction of estrus and pregnancy rates in anestrous bitches. [2007.09]
[Early pleuropulmonary toxicity associated with cabergoline, an antiparkinsonian drug] [2007.09]
Efficacy and tolerability of Entacapone versus Cabergoline in parkinsonian patients suffering from wearing-off. [2007.08.15]
Substantial shrinkage of adenomas cosecreting growth hormone and prolactin with use of cabergoline therapy. [2007.07]
Efficacy and tolerability of entacapone versus cabergoline in parkinsonian patients suffering from wearing-off. [2007.05.21]
Assessment of valvulopathy in Parkinson's disease patients on pergolide and/or cabergoline. [2007.05]
Dopamine agonist cabergoline reduces hemoconcentration and ascites in hyperstimulated women undergoing assisted reproduction. [2007.04.24]
Spectrophotometric determination of dopaminergic drugs used for Parkinson's disease, cabergoline and ropinirole, in pharmaceutical preparations. [2007.04]
Treatment of spontaneous pyometra in 22 bitches with a combination of cabergoline and cloprostenol. [2007.03.03]
Comparison of the effect of gonadotropin-releasing hormone analog (Diphereline) and Cabergoline (Dostinex) treatment on uterine myoma regression. [2007.03]
[Risperidone-induced symptomatic hyperprolactinemia in youth with schizophrenia: efficacy and tolerability of cabergoline treatment] [2007.03]
Effectiveness of long-term cabergoline treatment for giant prolactinoma: study of 12 men. [2007.02]
Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. [2007.01]
SUNCT syndrome in a patient with prolactinoma and cabergoline-induced attacks. [2007.01]
Cerebrospinal fluid leakage as complication of treatment with cabergoline for macroprolactinomas. [2006.12]
Cabergoline reverses cortical hyperexcitability in patients with restless legs syndrome. [2006.10]
A combination of oral cabergoline and double cloprostenol injections to produce third-quarter gestation termination in the bitch. [2006.09]
Effectiveness of treating ovarian hyperstimulation syndrome with cabergoline in two patients with gonadotropin-producing pituitary adenomas. [2006.09]
[Use of cabergoline in persisting Cushing's disease] [2006.09]
Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial. [2006.07]
Cabergoline treatment in men with psychogenic erectile dysfunction: a randomized, double-blind, placebo-controlled study. [2006.05.18]
Drug insight: Cabergoline and bromocriptine in the treatment of hyperprolactinemia in men and women. [2006.04]
Cabergoline scavenges peroxynitrite enhanced by L-DOPA therapy in patients with Parkinson's disease. [2006.04]
The influences of hyperprolactinemia and obesity on cardiovascular risk markers: effects of cabergoline therapy. [2006.04]
The treatment with cabergoline for 24 month normalizes the quality of seminal fluid in hyperprolactinaemic males. [2006.03]
Effect of clarithromycin on the pharmacokinetics of cabergoline in healthy controls and in patients with Parkinson's disease. [2006.01]
Efficacy and safety of high-dose cabergoline in Parkinson's disease. [2006.01]
Treatment of Japanese restless legs syndrome patients with cabergoline: an open clinical preliminary trial. [2006]
The use of high-dose daily cabergoline in an adolescent patient with macroprolactinoma. [2005.06]
Retrospective evaluation of cardio-pulmonary fibrotic side effects in symptomatic patients from a group of 234 Parkinson's disease patients treated with cabergoline. [2005.05]
Dopamine agonist cabergoline inhibits levodopa-induced caspase activation in 6-OHDA-lesioned mice. [2005.01]
Effect of cabergoline treatment on Cushing's disease caused by aberrant adrenocorticotropin-secreting macroadenoma. [2004.12]
A fatal overdose of the ergot derivative cabergoline. [2004.11.10]
Massive reduction of tumour load and normalisation of hyperprolactinaemia after high dose cabergoline in metastasised prolactinoma causing thoracic syringomyelia. [2004.10]
Cabergoline addition to depot somatostatin analogues in resistant acromegalic patients: efficacy and lack of predictive value of prolactin status. [2004.08]
|
